Recursion Pharmaceuticals Inc
RXRXHealthcare|Biotechnology|USA
$3.56
-0.21 (-5.57%)
Tangible Book
$1.08
Upcoming Data Readouts (5)
Jun 2027
Est. completion
P1P2Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
NCT05552755n=67
Jan 2028
Est. completion
P1P2Head and Neck Squamous Cell Carcinoma (HNSCC)
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655n=230
Jun 2028
Est. completion
P1Relapsed or Refractory B-cell Malignancies
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116n=85
Oct 2028
Est. completion
P1P2Unresectable
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659n=170
Mar 2029
Est. completion
P1Solid Tumor
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198n=40